BioSpace News Archive

TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced that management will present virtually at the following upcoming medical meeting and healthcare conferences: The Society for Immunotherapy of Cancer Annual Meeting (SITC) Gavin MacBeath, Ph.D., Chief Scientific Officer, will present an e- poster entitled

Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases, showed significantly greater ACR 20 responses compared to placebo at 16 weeks and met all key secondary endpoints Deucravacitinib was well-tolerated with a safety profile consistent with prior studies

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced it will present a corporate overview at the following investor conferences

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion ® in the cosmetic surgery market and J-Plasma ® in the hospital surgical market, today announced that it has completed subject enrollment in a U.S. Investigational Device Exemption (IDE) clinical study evaluating the use of its Renuvion ® Technol

Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6 th Annual Israel Conference on November 12, 2020

Based on interim Phase 1/2 results, a single 7.5 µg dose of ARCT-021, along with prime-boost regimens are selected to advance into later stage global clinical trials Seroconversion in majority of participants receiving doses in the range of 5 µg to 7.5 µg; Geometric Mean Titer (GMT) levels for neutralizing antibodies in the range of convalescent plasma

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA ® ▼ (Dinutuximab Beta) in China

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the third calendar quarter of 2020. PolarityTE will host a conference call and webcast today, November 9, 2020 at 8:00 a.m. ET.

Heat Biologics, Inc. (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the third quarter

Stryker announced that Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol Myers Squibb, has been elected to its Board of Directors, effective December 1, 2020.